EN DE
Watch Tandem Diabetes Care Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Tandem Diabetes Care Inc (TNDM) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Tandem Diabetes Care Inc stock $15.40, price $18.71, that is 17.7% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

TD Tandem Diabetes Care Inc logo Thin data Nov 11, 2026

Tandem Diabetes Care Inc

TNDM · US
Expensive, weak quality

Our calculation puts a fair price 18% below what the stock costs today.

Expensive Growth (revenue 5y +15.3 %/yr in USD)
Insiders sold $32,555 (6M)
Profit last quarter 37% below a year ago.
Fair value $15.40 · Overvalued
Quality 37/100
Loss-making · -4.6% net margin (TTM)
High debt
Negative free cash flow
Trails peers (2/10)
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Tandem Diabetes Care Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$153.21 $10.12 Fair Value $15.40 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $10.12 – $153.21 · fair‑value band $11.55 – $19.25 · the $18.71 price screens above the $15.40 fair value. As of Nov 11, 2026.

Follow Tandem Diabetes Care in your weekly email

Every Wednesday you see whether Tandem Diabetes Care is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.

Show moreShow less

The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body.

In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data.

The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems.

The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Stock analysis

Tandem Diabetes Care Inc (TNDM) currently trades at $18.71, while our estimate is $15.40, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $11.55 (bear) to $19.25 (bull), the price of $18.71 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Tandem Diabetes Care Inc reported revenue of $1.0B in FY2025 versus $703M in FY2021, a compound +9.6%/yr. Reported net income was −$205M in FY2025.

Key figures

Market cap $1.3B Small · P/S ratio 1.18 · EPS (TTM) $−0.7000 · Net margin −4.6% · Return on equity −36.7% · Return on assets (EBIT) −10.0% (5-year average) · Operating margin −0.8% · Revenue (TTM) $1.1B.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 46% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −18%, TNDM screens richer than that median.

Fair Value

Bear $11.55 Fair Value $15.40 Bull $19.25
Price $18.71 · Downside -17.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 12
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 8
How calm the share price moves, does not count
Price momentum 44
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 44
Distance to the 52-week high, does not count
New shares 65
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director sold shares worth $32,555 and none bought.

  • SaleChristopher J TwomeyDirector1,700 shares at $19.15$32,555Oct 27, 202610b5-1 plan
  • SaleMark David NovaraEVP & CHIEF COMMERCIAL OFFICER2× since Mar 5, 2026: 189 shares, avg. $23.05$4,356Mar 17, 202610b5-1 plan

Plus 27 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+7.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.3%
Start year 2020 (pandemic). Over 10 years: +30.1% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+58.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1.6% (2020) → −7.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

TNDM screens overvalued: fair value 18% below the price. Compare with Abbott Laboratories, →

Compare Tandem Diabetes Care Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 2/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 37 · Bottom 25%
Fair Value upside −17.7% · Below median
Profitability
Return on assets −23.2% · Bottom 25%
Net margin (12 months) −4.6% · Below median
Operating margin (12 months) −0.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 13.8% · Above median
Balance sheet
Debt / equity 2.00× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 8.25× · Priciest 25%
P/S (12 months) 1.19× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 17
FUTURE (revenue growth)69 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs TNDM
DexCom, Inc DXCM $79.92 $89.18 +12% vs TNDM
Stryker Corporation SYK $324.29 $358.30 +10% vs TNDM
STERIS plc STE $257.12 $279.53 +9% vs TNDM
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs TNDM
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs TNDM
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs TNDM
Abbott Laboratories, ABT $110.46 $75.28 −32% vs TNDM
Medtronic plc MDT $101.59 $65.61 −35% vs TNDM
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs TNDM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tandem Diabetes Care Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Tandem Diabetes Care Inc Fair Value". https://www.fairvalue-calculator.com/stock/TNDM

Frequently asked questions

Is Tandem Diabetes Care Inc (TNDM) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $15.40 versus a price of $18.71, about 18% lower (overvalued).
What is the fair value of TNDM?
Our estimate for Tandem Diabetes Care Inc is $15.40 (as of Nov 11, 2026), built from audited fundamentals. The current price: $18.71.
What is the quality score of TNDM?
Tandem Diabetes Care Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tandem Diabetes Care Inc (TNDM)?
Our calculated price target is the estimate of $15.40 (as of Nov 11, 2026). Cautious scenario $11.55, optimistic scenario $19.25. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Tandem Diabetes Care Inc stock forecast for 2026?
Our estimate puts fair value at $15.40, about 18% lower versus a price of $18.71 (overvalued). Cautious scenario $11.55, optimistic scenario $19.25. The calculation is refreshed regularly with new filings.
What is the revenue of Tandem Diabetes Care Inc (TNDM)?
Tandem Diabetes Care Inc reported trailing-twelve-month revenue of about $1.1B (latest available figure, as of Nov 11, 2026).
What is the intrinsic value of Tandem Diabetes Care Inc (TNDM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tandem Diabetes Care Inc it is $15.40 per share (as of Nov 11, 2026), against a price of $18.71.
Is Tandem Diabetes Care Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, TNDM trades above its calculated fair value: price $18.71, fair value $15.40, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TNDM?
No. The price is what the market pays today ($18.71); the fair value is what the company's own numbers justify ($15.40). For Tandem Diabetes Care Inc the two are $3.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tandem Diabetes Care Inc worth?
The market values Tandem Diabetes Care Inc at about $1.3B (market capitalisation, as of Nov 11, 2026). Per share that is $18.71; our models calculate a fair value of $15.40 per share.
What do the bullish and bearish scenarios say about TNDM?
Our models span a range for Tandem Diabetes Care Inc: cautious scenario $11.55, base $15.40, optimistic $19.25 per share (as of Nov 11, 2026, price $18.71). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Tandem Diabetes Care Inc (TNDM)?
Balance-sheet figures for Tandem Diabetes Care Inc (as of Nov 11, 2026): return on equity −36.7%, debt of 2.00 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is TNDM from its 52-week high?
Tandem Diabetes Care Inc trades at $18.71, about 34% below its 52-week high of $28.26 and 46% above the low of $12.82 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $15.40 is for.
Which stocks are comparable to Tandem Diabetes Care Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tandem Diabetes Care Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $18.71, calculated fair value $15.40 (−18%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Tandem Diabetes Care Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tandem Diabetes Care Inc (TNDM)?
The closing price on Nov 10, 2026 was $18.71. Our estimate is $15.40, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tandem Diabetes Care Inc right now?
Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Tandem Diabetes Care Inc

How large is the market capitalisation of Tandem Diabetes Care Inc (TNDM)?
The market capitalisation of Tandem Diabetes Care Inc is $1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tandem Diabetes Care Inc (TNDM)?
The price-to-sales ratio of Tandem Diabetes Care Inc is 1.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tandem Diabetes Care Inc (TNDM)?
Earnings per share at Tandem Diabetes Care Inc are $−0.7000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tandem Diabetes Care Inc (TNDM)?
The net margin of Tandem Diabetes Care Inc is −4.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tandem Diabetes Care Inc (TNDM)?
The return on equity (ROE) of Tandem Diabetes Care Inc is −36.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tandem Diabetes Care Inc (TNDM)?
On an EBIT basis the return on assets of Tandem Diabetes Care Inc is −10.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tandem Diabetes Care Inc (TNDM)?
The operating margin of Tandem Diabetes Care Inc is −0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tandem Diabetes Care Inc (TNDM)?
Revenue at Tandem Diabetes Care Inc is growing +13.8% versus a year earlier (3y avg +8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tandem Diabetes Care Inc (TNDM)?
Earnings per share at Tandem Diabetes Care Inc are growing −37.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Tandem Diabetes Care Inc (TNDM) generate?
The free cash flow of Tandem Diabetes Care Inc is −$29.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Tandem Diabetes Care Inc (TNDM) carry?
The net debt of Tandem Diabetes Care Inc is $354M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Tandem Diabetes Care Inc in the live analysis

One click puts Tandem Diabetes Care Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.